Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Decreases By 28.6%

enGene Holdings Inc. (NASDAQ:ENGNW) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 2,052 shares, a drop of 28.6% from the November 30th total of 2,873 shares. Based on an average daily volume of 12,801 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 12,801 shares, the days-to-cover ratio is currently 0.2 days.

enGene Price Performance

Shares of enGene stock traded down $0.14 on Monday, reaching $3.00. The company had a trading volume of 154 shares, compared to its average volume of 11,139. enGene has a 1 year low of $0.51 and a 1 year high of $3.80. The firm’s 50-day moving average price is $2.44 and its two-hundred day moving average price is $1.42.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.